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Abstract 
Objective  
To investigate the diagnostic accuracy of rheumatoid factor (RF) as a test for rheumatoid arthritis (RA) in 
primary care and impact on referral times using the Clinical Practice Research Datalink. 
Methods  
We identified all patients with a first RF test recorded in the CPRD between 1/1/2000 and 31/12/2008 and 
those diagnosed with RA within two years of testing. We calculated likelihood ratios (LRs), sensitivity, 
specificity and predictive values (PVs) of RF for a diagnosis of RA. We compared time to hospital referral 
in those testing positive and negative using Kaplan Meier failure curves and Log Rank tests.  
Results 
Of 62436 first RF tests, 4679 (7.5%) were positive. There were 1753 incident cases of RA of which 57.8% 
were sero-positive. The LR+ for RF was 9.5 (CI95 9.0 to 10.0) and LR- was 0.5 (CI95 0.4 to 0.5). Sensitivity 
and specificity were 57.8% (CI95 55.4% to 60.1%) and 93.9% (CI95 93.7% to 94.1%) and PPV and NPV 
were 21.4% (CI95 20.3% to 22.6%) and 98.7% (CI95 98.6% to 98.8%) respectively. Median time to first 
hospital contact after first RF test in those with sero-positive vs sero-negative results was 54 days (CI95 49 to 
58) vs 150 (CI95 147 to 152).  
Conclusions  
Only 2.8% of patients undergoing RF testing were diagnosed with RA, suggesting RF is used to screen 
patients with musculoskeletal symptoms rather than those with more specific features of RA. A positive RF 
may be helpful in diagnosing RA in primary care but performs badly in excluding RA and may delay 
referral.  
Key words: sensitivity specificity, rheumatoid factor, rheumatoid arthritis, primary care.  
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Introduction 
Rheumatoid arthritis (RA) is a destructive inflammatory joint disease. Bone oedema leading to erosions has 
been demonstrated as early as 4 weeks after symptom onset[1] and early referral of patients with suspected 
RA for treatment with disease modifying anti-rheumatoid drugs (DMARDS) is advocated in order to prevent 
long term joint damage and disability.[2-5] Many GPs undertake investigations to support early diagnosis 
and guide referrals and this may include testing for rheumatoid factor (RF).[6, 7] RF has a pooled sensitivity 
of 69% (65% to 73%) and specificity of 85% (82% to 88%)[8] and has an established role in the 
classification of RA.[9] NICE guidelines specifically advise against a delay in urgent referral of patients 
with persistent synovitis who have a negative RF.[2] However, RF results have been shown to influence 
referral decisions and GPs may use a negative test to exclude RA despite the presence of clinical features 
suggesting the disease.[6, 10] This may lead to a delay in diagnosis for patients with RF negative disease, 
and referral of patients with a false positive test and poor clinical evidence of disease.  
Most studies on the diagnostic utility of RF have taken place in early arthritis clinics in secondary care 
where the pre-test probability of RA is relatively high. Few studies have been conducted in general practice 
where the pre-test probability of RA is low.[6, 10, 11] However,  most RF testing takes place in primary 
care.[11] It is important for GPs and patients to have information on the usefulness of RF in excluding RA 
or supporting referral. Our primary aim was to determine the diagnostic value of RF for RA in primary care 
by estimating likelihood ratios, sensitivity, specificity and predictive values using data from the UK Clinical 
Practice Research Datalink (CPRD). Our secondary aim was to determine the prognostic impact of the RF 
result on time to referral to secondary care. 
Methods                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Data Source 
The UK Clinical Practice Research Datalink (CPRD) is the world’s largest longitudinal primary care 
database containing data for approximately 13.3 million individuals registered with 613 UK primary care 
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practices. It has been found to be generally representative of the UK population.[12] GPs use a coded 
thesaurus of clinical terms, called Read Codes, to record clinical features, laboratory tests and results, 
diagnoses, and other information. We had access to Read codes but not to supplemental free text.  
Ethical Approval  
The study protocol was approved by the Independent Scientific Advisory Committee (ISAC) for the CPRD, 
protocol number 10_105R.  
 
Study Population 
The study period ran from 1st January 2000 to 31st December 2010. Patients had contributed at least 12 
months of research standard data to the CPRD before the date of their first RF test, and at least two years of 
follow up data subsequently, unless they died during the two years’ follow-up in which case they were 
included to date of death.  
 
We identified all RF tests recorded as a RF titre or a Read code for a positive or negative RF test in the 
CPRD records of permanently registered patients aged 16 and over between 1st January 2000 and 31st 
December 2008. The first test in each patient’s record was identified and patients with a record of a RF test 
before the study period were excluded. During the course of the study we observed a bias in the way RF was 
recorded in the CPRD with tests being more likely to be recorded if positive(13) and negative tests either 
being recorded without a RF titre or not recorded at all, possibly because positive tests are more clinically 
meaningful to GPs. Where there was evidence of preferential data recording, missing data were considered 
to be Missing Not at Random (MNAR)(14, 15). In order to minimise the impact of selection bias thus 
introduced, we stratified the data by general practice and calendar year (‘practice-years’) and excluded 
practice-years where the proportion of positive tests was >20%. This cut-off was based on a study by Miller 
et al(11) that found that the mean percentage of positive RF tests in primary care was 6.3%. Based on a 
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comparison of the distribution of the percentage of positive RF tests against that for the study by Miller, we 
considered that it was likely that practice-years with >20% of positive tests were likely to be preferentially 
recording positive tests and were thereby MNAR; the full methods of this investigation are described 
elsewhere(13). The remaining tests were from practice-years where missing data were likely to be missing at 
random, allowing for a complete case analysis to be conducted with a lower risk of selection bias(15). From 
this dataset we then selected tests where a test result or RF titre was available.  
 
We excluded patients with a diagnosis of RA more than three months before their first RF test, those with 
pre-existing connective tissue diseases (systemic lupus erythematosus, poly/dermatomyositis, systemic 
sclerosis and Sjogren’s syndome), or with psoriasis or inflammatory bowel disease at any time.  
Classification of RF test results 
RF results were classified as positive if the recorded titre was above the upper value of the normal range 
(UNR) in the electronic test record or there was a Read code for a positive RF in the medical records. Where 
normal ranges were not recorded we assumed that a practice had sent all RF tests to the same laboratory 
during that calendar year and imputed the UNR value as the mode value stratified by year and general 
practice. Due to the variation in the UNR cut-off we calculated the difference between the RF titre and the 
UNR cut-off value in order to investigate the relationship between RF titre and RA diagnosis. We denoted 
this as the ‘off-set’ RF value.  
Identifying cases of rheumatoid arthritis (RA) 
We searched the medical records of the study population for patients with a diagnosis of RA up to two years 
following the first RF test. We based our case identification on the algorithm validated by Thomas et al.[16] 
Those with a Read code for sero-positive or erosive disease and those with at least one prescription for a 
DMARD within two years of diagnosis were classified as cases of RA; those with more than one record of 
RA diagnosis but without any prescriptions for DMARDs were classified as ‘probable’ RA. Identification of 
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cases of RA was undertaken without knowledge of the RF result. The date of RA diagnosis was taken as the 
first record of RA or date of first prescription for a DMARD, whichever was earlier.  
Covariate identification 
For each patient in the study population we determined smoking status and body mass index records nearest 
to their first RF test.  The presence of pre-existing diabetes mellitus was determined using a previously 
described algorithm.[17] Pre-existing thyroid disease and cancer in the year before diagnosis was 
determined. The individual socioeconomic status was not available for every patient in the study population; 
therefore, we used the general practice Index of Multiple Deprivation (IMD) score quintile where a score of 
five indicates the highest level of deprivation.  
Time from RF test to hospital referral or attendance  
We identified all records of referral, outpatient clinic attendance and inpatient discharge summaries that 
were coded as having a rheumatology specialty and determined the earliest date as first contact with 
rheumatology. Specialty-specific data are inconsistently recorded on the CPRD; therefore we identified all 
records of hospital referral, outpatient clinic attendance, letters and inpatient discharge summaries, and 
determined the earliest date of contact with any hospital department. 
 Statistical analyses 
All analyses were undertaken using STATA Statistical Software version 12 (StataCorp. 2011. Stata: Release 
12. Statistical Software. College Station, TX: StataCorp LP). 
We calculated the positive and negative likelihood ratios (LRs), sensitivity, specificity and predictive values 
(PVs) of RF for a diagnosis of RA in patients with positive or negative RF tests. We performed sensitivity 
analyses excluding patients with “probable RA”, and to determine the effect of classifying a patient as 
having RA if the RF value was equal to or above the upper normal range value. We performed a sensitivity 
analysis of all test data in the original study population, including data that were considered to be MNAR to 
quantify the impact of this on the measures of diagnostic accuracy.  Modified Poisson regression models 
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with robust variance estimates [18] were used to calculate the relative risks (RRs) for a diagnosis of RA 
within two years associated with increasing offset RF titre values.  
The distribution of baseline characteristics of patients with positive and negative RF test results was 
compared using chi-square tests. Modified Poisson regression models [18]  were used to calculate adjusted 
RRs characteristics found to be associated with a positive RF test including co-morbidity and records of 
musculoskeletal symptoms in the six months before the test. Variables were selected for inclusion into the 
model using forwards stepwise Poisson regression models set to accept variables at a significance of 
p≤0.2.[19] Cox proportional hazards models were used to calculate the hazard ratio of death within two 
years of first RF test. We constructed Kaplan-Meier failure curves to investigate the effect of a positive and 
negative RF result on referral times to a rheumatologist and to any hospital contact following first RF test. 
Log rank tests were used to determine the equality of the failure curves in those with positive and negative 
RF tests.  
Results 
There were 91 293 eligible first RF tests with a test result recorded on the CPRD during the study period. 
We excluded 28 857 tests from practice-years where there was evidence that missing data were MNAR or 
there was an exclusion diagnosis present, resulting in a final study population of 62 436 RF tests. The 
number of eligible tests that were included increased from 2234 in 2000 to 9167 in 2008. This is likely to 
reflect a change from manual to automatic recording of test results. There were 4697 (7.5%) positive and 57 
739 (92.5%) negative tests. 42 545 (68.1%) were undertaken in females.  Forty-four patients (0.08%) with a 
negative first RF test had a subsequent positive test within two years of their first test.   
Table 1 shows the baseline characteristics of the study population stratified by RF test result. The mean age 
of patients who were RF(+) was significantly older than those who were RF(-); mean difference 6.0 years 
(95% CI 5.6 to 6.5). Current smokers and those with unknown smoking status were more likely to have a 
positive test result relative to non-smokers. Those with a BMI< 20 had an increased risk relative to those 
with a   BMI between 20 and 24.  
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 1091 patients died within two years of their first RF test of whom 186 (17.1%) had a positive result. The 
adjusted HR for death within two years of first RF result was 1.5 (95% CI 1.3 to 1.8) after adjustment for 
age, sex and all variables found to be associated with a positive RF test. 
Diagnostic accuracy of RF testing 
There were 1740 incident cases of RA; 1285 of these had a record of a DMARD prescription after their date 
of RA diagnosis. 455 had no DMARD prescriptions within two years and were classified as ‘probable’ RA. 
1005 (57.8%) of the RA cases had a positive and 735 (42.2%) a negative first RF result. Of those without a 
diagnosis of RA within two years, 3692 (6.1%) had a positive and 57 004 (93.9%) a negative RF test. Table 
2 shows the results of the diagnostic accuracy analysis and Table 3 demonstrates that the relative risk for a 
diagnosis of RA increased with increasing RF titre. 
Referral to secondary care 
Of the 62 436 patients with a first RF test during the study period, 1695 had a referral to rheumatology prior 
to the date of their first RF and were excluded from the analysis of referral times leaving 60 741 eligible 
patients. Figure 1 shows the Kaplan-Meier failure curves for contact with a rheumatology department in the 
two years following the first RF test. The Kaplan-Meier curve illustrates that when contact with 
rheumatology services occurred, it tended to be a short time after the first RF test. A higher proportion of 
patients with a RF(+) test were referred to rheumatology within two years of testing (p<0.0001). 3924 
(86.9%) of the patients with a RF(+) test and 44 335 (78.9%) of those with a RF(-) test had a record of any 
hospital contact within two years of their first RF test. Figure 2 shows the Kaplan-Meier curve for contact 
with any hospital department in the two years following first RF test. A higher proportion of patients with a 
RF(+) test were seen in hospital after their first RF test (p<0.0001).  
For patients with a record of contact with a rheumatologist after their first RF test, the median referral time 
was 21 days (IQR 11, 60) in patients with a RF(+) test and 42 days (IQR 14, 193) in those with a (RF-) 
result. In those with a record of contact with any hospital department after their first RF test the median time 
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to contact was 33 days (IQR 11, 128 days); in those with a RF(+) test and 79 days (IQR 20, 247 days) with a 
RF(-) test. 
Discussion 
We report the diagnostic utility of RF in a large electronic dataset of primary care patients representing 
approximately 8.4% of the UK population. RF was found to be highly specific with a moderately good 
positive likelihood ratio of 9.5 (95% CI 9.0 to 10.0). However, its sensitivity was low and the negative 
likelihood ratio was poor at 0.5 (95% 0.4 to 0.5). The first RF test was positive for 57.8% incident cases of 
RA and higher titres were associated with a diagnosis of RA. We demonstrated a rise in the relative risk of a 
positive test with increasing age and a higher risk of death with a positive RF (RR 1.5). We demonstrated a 
delay in referral of patients with a negative RF result to rheumatology and to hospital in general, although 
78.9 to 86.9% patients undergoing testing were referred for hospital review in the two years following the 
test.  
The main strength of the study is that it is based in a primary care population, where most RF requests take 
place and is the largest study to date of the utility of RF as a test for RA in this setting. The CPRD is an 
observational dataset consisting of records kept by GPs in day to day patient management. It is a valuable 
resource for large epidemiological studies but has limitations, for example, the loss of patients to follow-up 
when they change practice and the lack of valid data prior to their entry onto the database. Diagnoses are 
recorded using Read codes and consequently definition of cases may be hampered by variation in recording 
methods. We identified cases of RA using an algorithm based on that validated by Thomas et al[16] with a 
sensitivity of 84% [95% CI 73 to 94%] and specificity 86% [95% CI 72 to 92%]. These figures suggest that 
a number of cases with Read codes for RA might be misclassified, introducing potential bias in our results.  
The sensitivity analyses showed that the likelihood ratios from the primary analysis were robust in excluding 
‘probable’ cases of RA but that changes to the definition of a positive RF test (sensitivity analysis (b)) and 
the inclusion of data that were considered to be MNAR (sensitivity analysis (d)) resulted in a substantial 
decrease in the LR+. When data that were considered to be MNAR were included, the proportion of positive 
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tests in the study population increased from 7.5% to 19.5% and the proportion of negative tests decreased 
from 92.5% to 80.5% resulting in a reduction in the LR+ but a stable LR-. Our analysis demonstrates the 
preferential recording of positive tests on the CPRD. The change from manual to automatic coding of test 
results on the CPRD was reflected in the increase in eligible tests from the beginning to the end of the study 
period. However, we do not have the practice-specific data regarding the dates of this change. Since we 
would expect 6.3% of RF tests in primary care to be positive, we have shown that the inclusion of data that 
are MNAR gives rise to the analysis of a biased population. 
.  
We acknowledge that people diagnosed with RA on clinical grounds and referred directly without RF testing 
in primary care were not included, and that not all study participants were assessed by a rheumatologist for 
the presence or absence of RA. This may have introduced detection bias because RF(+) patients were more 
likely to be referred to hospital, and RF(-) patients might have not been referred during the two year follow-
up period, resulting in a higher specificity than expected.  
Forty two per cent of patients diagnosed with RA had a negative first RF test in primary care which is 
comparable with a cohort of 1892 patients with new RA where 37% RF tests were negative.[20] In Table 4 
we have compared our results with those of a meta-analysis[8] and pooled values from a systematic 
review.[21] The sensitivity of RF was lower in early arthritis studies suggesting poorer utility earlier in the 
disease and consistent with our results. A poor negative likelihood ratio is reported throughout the literature. 
Our finding that a positive RF is associated with an increased risk of death is in keeping with other 
population studies[22] although the risk estimate might be confounded by the development of comorbidity 
after diagnosis. In general a positive likelihood ratio greater than 10 and a negative likelihood ratio less than 
<0.1 are considered to provide strong evidence to rule in or rule out diagnoses respectively.[22, 23]  This 
study, and previous analyses,[8, 21] have demonstrated the positive likelihood ratio for RF to be less than 10 
and the negative likelihood ratio to be greater than 0.1 indicating moderate performance ruling in and poor 
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performance ruling out RA. Whilst higher titres are associated with a greater likelihood of the patient having 
RA, a negative test does not exclude it.  
Only 2.8% of patients undergoing RF testing had a final diagnosis of RA suggesting that RF is used to 
screen patients presenting with musculoskeletal symptoms, rather than to support a diagnosis in patients 
with specific features of RA. This is in keeping with  a recent UK study of RF requests in primary care 
where 5.8% of tests were positive and 4% had an eventual diagnosis of RA.[11]According to 2010 
ACR/EULAR criteria,[9] RF has an important role in the diagnosis of RA. The low diagnostic yield 
demonstrated in primary care is largely due to incorrect use or interpretation. Up to 87% patients undergoing 
RF testing were referred to hospital and a positive RF was associated with a much reduced time to first 
hospital contact in comparison to those with a negative RF test. This may be either because patients with a 
RF(+) are more unwell and referred on clinical grounds, or that a RF result influences referral decisions. The 
main question raised in our study is whether RF should be requested and how it should be interpreted in 
primary care. These are also relevant questions for other immunological tests such as antinuclear antibodies 
and anti-citrullinated protein antibody (ACPA). It has been suggested that ACPA might be useful as a 
screening test for RA because of its high specificity and similar sensitivity to RF[24] and used to guide 
referrals in patients with suspected inflammatory joint disease.[25] However, if used indiscriminately in 
patients with a low pre-test probability of RA, neither a positive RF nor a positive ACPA test result affect 
clinical probabilities sufficiently to secure a diagnosis[26] and its utility as a test would be hampered by the 
same problems of over-use and over-interpretation.  
Key messages 
 Only 2.8% of patients undergoing RF testing in primary care are subsequently diagnosed with RA 
 A negative RF test should not be used as evidence for the absence of RA 
 Patients with symptoms consistent with RA should be referred to rheumatology for assessment 
without delay 
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Table 1. Characteristics of patients with positive and negative RF tests 
Characteristic 
Negative RF 
test 
n (%) 
Positive RF 
test 
n (%) 
RR (CI 95%) 
or p-value 
adjRR* 
Males 18 318 (92.1) 1573 (7.9) 1.0 1.0 
Females 39 421 (92.7) 3124 (7.3) 0.9 (0.9,1.0) 1.0 (1.0, 1.1) 
Mean age (SD) 51.4 (15.6) 57.5 (15.4) 1.0 (1.0, 1.0)  1.0 (1.0, 1.0) 
Pre-existing thyroid disease 
No 52 923 (91.6) 4275 (92.1) 1.0 1.0 
Yes 4819 (8.4) 419 (8.9) 1.1 (1.0,1.2) 0.9 (0.8, 1.0) 
Cancer within 1 year before RF test 
No 57 227 (99.1) 4640 (98.9) 1.0 1.0 
Yes 515 (0.9) 54 (1.2) 1.3 (1.0, 1.6) 0.7 (1.2) 
Pre-existing diabetes mellitus 
None 54 629 (94.6) 4390 (93.5) 1.0 1.0 
Yes (Type 1 or Type 2) 3113 (5.4)  304 (6.5)  1.2 (1.1, 1.3) 1.0 (0.9, 1.1) 
Smoking status   
Non-smoker 35 199 (61.0) 2733 (58.2) 1.0 1.0 
Current smoker 10 095 (17.5) 913 (19.5) 1.2 (1.1, 1.2) 1.3 (1.2, 1.4) 
Smoking status unknown 12 448 (21.6) 1048 (22.3) 1.1 (1.0, 1.2) 1.3 (1.1, 1.5) 
Body Mass Index  
<20 2321 (4.0) 228 (4.9) 1.3 (1.1, 1.4) 1.4 (1.2, 1.6) 
20 - 24.9 14 166 (24.5) 1081 (23.0) 1.0 1.0 
25 - 29.9 15 052 (26.1) 1260 (26.8) 1.1 (1.0, 1.2) 1.0 (1.0, 1.1) 
30 - 34.9 7345 (12.7) 595 (12.7) 1.1 (1.0, 1.2) 1.0 (0.9, 1.1) 
35 – 39.9 2593 (4.5) 190 (4.1) 1.0 (0.8, 1.1) 1.0 (0.8, 1.1) 
40 and over 1109 (1.9) 94 (2.0) 1.1 (0.9, 1.4) 1.2 (1.0, 1.4) 
BMI unknown 15 153 (26.2) 1249 (26.6) 1.2 (0.9, 1.4) 1.1 (0.9, 1.4) 
General Practice IMD quintile 
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1 (least deprived) 11 034 (19.1) 840 (17.9) 1.0 1.0 
2 8957 (15.5) 673 (14.3) 1.0 (0.9, 1.1) 0.9 (0.8, 1.1) 
3 11 169 (19.3) 943 (20.1) 1.1 (1.0, 1.2) 1.1 (1.0, 1.2) 
4 12 137 (21.0) 1009 (21.5) 1.1 (1.0, 1.2) 1.1 (1.0, 1.2) 
5 (most deprived) 14 445 (25.0) 1229 (26.2) 1.1 (1.0, 1.2) 1.2 (1.1, 1.3) 
* Adjusted for age and all other variables in the table. Results shown in bold are statistically significant. IMD, Index 
of Multiple Deprivation. 
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Table 2. Diagnostic accuracy of RF test (a) including all RA cases and (b) excluding ‘probable’ cases of RA (c) using all RA cases but classifying tests 
where the RF titre was equal to the upper normal range for the RF test as positive rather than negative and (d) including all original data (including 
data considered to be MNAR).  
 Primary analysis (a) Sensitivity analysis (b) Sensitivity analysis (c) Sensitivity analysis (d) 
 RA diagnosis 
No RA 
diagnosis 
RA diagnosis 
No RA 
diagnosis 
RA diagnosis 
No RA 
diagnosis 
RA diagnosis 
No RA 
diagnosis 
RF test positive 1005(1.6%) 3692(5.9%) 745(1.2%) 3949(6.3%) 1096(1.8%) 12 533(20.1%) 2184(2.4%) 15 663(17.2%) 
RF test negative 735(1.2%) 57 004(91.3%) 540(0.9%) 57 202(91.6%) 644(1.0%) 48 163(77.1%) 1047(1.1%) 72 399(79.3%) 
Diagnostic 
Accuracy 
Estimate 95% CI Estimate 95% CI Estimate 95% CI 
Estimate 95% CI 
LR+ 9.5 9.0 to 10.0 9.0 8.5 to 9.5 3.1 2.9 to 3.2 3.8 3.7 to 3.9 
LR- 0.5 0.4 to 0.5 0.5 0.4 to 0.5 0.5 0.4 to 0.5 0.4 0.4 to 0.4 
Sensitivity 57.8% 
55.4% to 
60.0% 
58.0% 55.2% to 60.7% 63.0% 60.7%  to 79.7% 
67.6% 66.0% to 69.2% 
Specificity 93.9% 
93.7% to 
94.1% 
93.5% 93.3% to 93.7% 79.4% 79.0%  to 79.7% 
98.6% 98.5% to 98.6% 
PPV 21.4% 
20.3% to 
22.6% 
15.9% 14.8% to 17.0% 8.0% 7.6% to 8.5% 
12.2% 11.9% to 12.5% 
NPV 98.7% 
98.6% to 
98.8% 
99.1% 99.0% to 99.1% 98.7% 98.6%  to 98.8% 
98.6% 98.5% to 98.6% 
RA, rheumatoid arthritis; LR+, positive likelihood ratio; LR- negative likelihood ratio; PPV, positive predictive value; NPV, negative predictive value.  
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Table 3. Risk of RA associated with the difference between the observed RF value and the upper 
normal range value provided by the laboratory 
Difference between RF titre and UNR 
value 
Rheumatoid Arthritis within 24 
months 
adjRR (CI 95%) 
 
No 
n (%) 
Yes 
n (%) 
RF value less than UNR 48 163 (79.4) 644 (37.0) 1.0 
RF value equal to UNR 8844 (14.6) 91 (5.2) 0.8 (0.6 to 1.0) 
1-99 IU/L above UNR 3245 (5.4) 555 (31.9) 10.0 (9.0 to 11.2) 
100-499 IU/L above UNR 382 (0.6) 354 (20.3) 28.5 (25.3 to 32.0) 
≥500 IU/L above UNR 62 (0.1) 96 (5.5) 33.2 (28.0 to 39.3) 
RF, rheumatoid factor; RA rheumatoid arthritis; UNR, laboratory upper normal range; adjRR, relative risk adjusted for adjusted for age,  sex, 
smoking status, BMI,  symptoms in the six months before RF test( hand symptoms, shoulder symptoms, knee symptoms, tenosynovitis, pre-
existing thyroid disease, back symptoms, neck symptoms), and general practice IMD score.   
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Table 4.  Diagnostic accuracy of RF compared with other studies 
Estimate of 
diagnostic 
accuracy 
Current study 
Nishimura et al 
meta-analysis (50 
studies)[8] 
Whiting et al Summary 
results (67 studies)[21] 
Whiting et al 
Summary results 
from only early 
arthritis studies 
[21] 
 Estimate (95% confidence interval) 
LR+ 9.5 (CI9.0 to 10.0) 4.86  (3.95 to 5.97) 3.3 (2.7 to 3.9) 4  (2.5 to 6.5) 
LR- 0.5 (0.4 to 0.5) 0.38  (0.33 to 0.44) 0.4  (0.35 to 0.42) 0.5(0.45 to 0.59) 
Sensitivity 57.8% (55.4% to 60.0%) 69%  (65% to 73%) 70% (66% to 73%), 56% (50% to 62%) 
Specificity 93.9% (93.7% to 94.1%) 85%  (82% to 88%) 79% (74% to 83%), 86% (78% to 92%) 
PPV 21.4% (20.3% to 22.6%)    
NPV 98.7% (98.6% to 98.8%)    
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Figure 1. Kaplan-Meier failure curve for contact with rheumatology in the two years following first 
RF test, stratified by RF test result 
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Figure 2. Kaplan-Meier failure curve for contact with any hospital department in the two years 
following first RF test, stratified by RF test result 
 
